According to a report by the World Health Organization (WHO), viral hepatitis infected 1.34 million people in 2015, a figure comparable to tuberculosis and higher than HIV. While mortality from tuberculosis and HIV is decreasing, the number of deaths from hepatitis virus is increasing. Here
In May 2016, 194 governments adopted the Global Health Strategy (GHSS) on viral hepatitis: "Towards an end to viral hepatitis, 2016-2020". Its aim is to eliminate the hepatitis virus – with particular emphasis on hepatitis B and C – as a target public health threat by 2030, reducing new infections and mortality by 90%. down 65%.
The theme of the World Hepatitis Campaign 2017 is to accelerate progress towards the elimination of this hepatitis.
More interference with testing and treatment.
In 2015, only 9% of people with HBV and 20% of people with HCV were diagnosed. 325 million people live with the hepatitis virus. However, less than 1% can be treated.
BioMérieux supports its goal of bridging testing and treatment. Most hepatitis deaths involve the hepatitis B and C viruses, but viral forms of hepatitis can also be fatal. According to the World Health Organization, an effective response to hepatitis testing requires tailored interventions for each virus. This is why we have developed two new automated hepatitis E tests soon to complete our solution for routine testing and confirmation of hepatitis A, B and C.
June 22, 2015– More than 70 world-renowned experts in the field of antibiotic resistance gathered in Annecy (France) to attend the first...
BioMérieux is honored to contribute to global awareness of antibiotic resistance by supporting Antibiotic Awareness Week.
At Marcy l'Étoile (France) - April 6, 2017 - bioMérieux, a longtime researcher in the field of in vitro diagnostics and a pioneer...
BioMérieux receives FDA approval to expand pathogen identification on VITEK® MS
BioMérieux's VIDAS® B • R • A • H • M • S PCT ™ became the first procalcitonin test approved by...
.png){kind=logo}
